Vanguard Capital Management Acquires 5.09% Stake in NeoGenomics Inc (NEO)

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, reporting a new 5.09% ownership stake in NeoGenomics Inc (NEO). As of the event date on March 31, 2026, Vanguard beneficially owns 6,610,272 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 6,610,272 shares, while possessing sole voting power over 954,449 shares. This position was acquired in the ordinary course of business and is not intended to influence or change the control of the issuer. The reported holdings include shares managed by various Vanguard affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. This filing marks an increase from a previous ownership level of 0.0%, establishing Vanguard as a significant institutional shareholder in the Fort Myers-based cancer diagnostics company.